Mobile

A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for Subjects with hepatitis C who are on dialysis for kidney disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003625-42

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the antiviral efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) • To evaluate the safety and tolerability of the treatment regimen

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens